As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a study that evaluated the pharmacokinetics, efficacy, safety, and immunogenicity of subcutaneous versus intravenous formulations of the infliximab biosimilar CT-P13 as maintenance therapy in patients with inflammatory bowel disease.
Independent expert commentary is provided by Professor Rupert Leong, Director of Endoscopy and Head of Inflammatory Bowel Disease Services at Concord Hospital, Clinical Discipline Head of Gastroenterology Macquarie University Hospital and Professor of Medicine at University of Sydney and Macquarie University.
Please login below to download this issue (PDF)